Quintiles Appoints Elgar Peerschke as President of Advisory Services
24 Febrero 2015 - 7:00AM
Business Wire
Quintiles today announced the appointment of Elgar Peerschke to
serve as president, Advisory Services. In this role, Peerschke is
responsible for leading Quintiles’ Advisory Services organization
and the continued development and delivery of its related
services.
Elgar Peerschke, newly appointed
president of Quintiles Advisory Services (Photo: Business Wire)
Bringing more than 25 years of experience to Quintiles, Elgar
joins Quintiles from Bain & Company, a global business
consulting firm, where he was a senior partner in its Global
Healthcare Practice Group and a leading client service partner.
Prior to Bain, Elgar spent more than a decade at McKinsey and
Company in various leadership roles.
“Throughout his career, Elgar has focused on the healthcare
industry, providing cutting-edge insight and guidance in boardrooms
of biopharmaceutical customers around the world,” said Tom Pike,
chief executive officer, Quintiles. “His deep experience working on
and developing innovative solutions for the biopharmaceutical
industry combined with his extensive leadership expertise across a
number of strategic and operational disciplines is a tremendous
addition to an already strong Quintiles team.”
Peerschke said, “I am extremely excited to be joining Quintiles
and leading its world-class Advisory Services organization. The
biopharmaceutical landscape continues to evolve at an incredible
pace that requires innovative thinking, diverse expertise and
flawless execution. I believe Quintiles – with its full-range of
services – is uniquely positioned to succeed in this environment,
enabling the connection of insights and superior delivery that
improves our customers’ probability of success.”
Peerschke earned his bachelor’s degree in political science from
Rutgers University and his MBA from New York University.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s
largest provider of biopharmaceutical development and commercial
outsourcing services. With a network of more than 32,000 employees
conducting business in approximately 100 countries, we helped
develop or commercialize all of 2013’s top- 100 best-selling drugs
on the market. Quintiles applies the breadth and depth of our
service offerings along with extensive therapeutic, scientific and
analytics expertise to help our customers navigate an increasingly
complex healthcare environment as they seek to improve efficiency
and effectiveness in the delivery of better healthcare
outcomes. To learn more about Quintiles, please visit
www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20150224005091/en/
QuintilesMari Mansfield, Media Relations
(mari.mansfield@quintiles.com)+1-919-998-2639orKarl Deonanan,
Investor Relations
(InvestorRelations@quintiles.com)+1-919-998-2789
Qimonda AG Ads (NYSE:QI)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Qimonda AG Ads (NYSE:QI)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024